IN2014CN04222A - - Google Patents

Info

Publication number
IN2014CN04222A
IN2014CN04222A IN4222CHN2014A IN2014CN04222A IN 2014CN04222 A IN2014CN04222 A IN 2014CN04222A IN 4222CHN2014 A IN4222CHN2014 A IN 4222CHN2014A IN 2014CN04222 A IN2014CN04222 A IN 2014CN04222A
Authority
IN
India
Prior art keywords
present
therapeutic agent
phosphatidic acid
joint diseases
destruction
Prior art date
Application number
Inventor
Kimiko Murofushi
Ikuko Masuda
Toshiro Morohoshi
Original Assignee
Sansho Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sansho Co filed Critical Sansho Co
Publication of IN2014CN04222A publication Critical patent/IN2014CN04222A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Abstract

The purpose of the present invention is to provide a therapeutic agent for joint diseases which has an activity of preventing the destruction of articular cartilages and has a high therapeutic effect. According to the present invention a therapeutic agent for joint diseases can be provided which comprises cyclic phosphatidic acid or carbacyclic phosphatidic acid as an active ingredient.
IN4222CHN2014 2011-11-11 2012-10-12 IN2014CN04222A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011247047 2011-11-11
PCT/JP2012/076478 WO2013069404A1 (en) 2011-11-11 2012-10-12 Therapeutic agent for joint diseases

Publications (1)

Publication Number Publication Date
IN2014CN04222A true IN2014CN04222A (en) 2015-07-17

Family

ID=48289788

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4222CHN2014 IN2014CN04222A (en) 2011-11-11 2012-10-12

Country Status (15)

Country Link
US (1) US9085593B2 (en)
EP (1) EP2803359B1 (en)
JP (1) JP5465815B2 (en)
KR (1) KR101953181B1 (en)
CN (1) CN103906519B (en)
AU (1) AU2012337087B2 (en)
BR (1) BR112014011315B8 (en)
CA (1) CA2855660C (en)
ES (1) ES2634008T3 (en)
HK (1) HK1199406A1 (en)
IN (1) IN2014CN04222A (en)
MY (1) MY168931A (en)
RU (1) RU2646457C2 (en)
SG (1) SG11201402226PA (en)
WO (1) WO2013069404A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI733108B (en) 2014-08-12 2021-07-11 日商大塚化學股份有限公司 Crystal of cyclic phosphonate sodium salt and its manufacturing method
JPWO2021132297A1 (en) 2019-12-23 2021-07-01
WO2022114058A1 (en) 2020-11-26 2022-06-02 Ｓａｎｓｈｏ株式会社 Therapeutic agent for pulmonary fibrosis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2700350B2 (en) 1990-04-20 1998-01-21 小糸工業株式会社 Vehicle detector
JP3195833B2 (en) 1991-09-30 2001-08-06 きみ子 室伏 New physiologically active substance and method for producing the same
JPH07149772A (en) * 1993-11-26 1995-06-13 Sagami Chem Res Center Activity promoter of protein phosphorylated enzyme c
JPH07258278A (en) 1994-03-18 1995-10-09 Sagami Chem Res Center Dna polymerase alpha inhibitor containing 1-o-acylglycerol-2,3-phosphate derivative as active ingredient
JPH0925235A (en) 1995-07-13 1997-01-28 Sagami Chem Res Center Suppressant for cancer metastasis containing 1-o-acylglycerol 2,3-phosphate derivative as active ingredient
JP2001178489A (en) 1999-12-24 2001-07-03 Kimiko Murofushi Method of producing cyclic phosphatidic acid
JP4836345B2 (en) * 2001-04-13 2011-12-14 きみ子 室伏 Neuronal survival promoter containing cyclic phosphatidic acid derivative
JP4815063B2 (en) * 2001-04-13 2011-11-16 きみ子 室伏 Drugs for promoting the proliferation, differentiation and / or survival of glial cells containing cyclic phosphatidic acid
EP1402894B1 (en) 2001-05-21 2007-12-26 Kimiko Murofushi Cancerous metastasis inhibitors containing carbacyclic phosphatidic acid derivatives
JP4162927B2 (en) 2002-06-11 2008-10-08 きみ子 室伏 Carbacyclic phosphatidic acid derivatives
RU2240131C1 (en) * 2003-04-04 2004-11-20 Аладьев Сергей Иванович Agent "artrovit" for prophylaxis and treatment of arthritis and arthrosis
CA2521189A1 (en) * 2003-04-11 2004-10-28 Gabor Tigyi Lysophosphatidic acid analogs and inhibition of neointima formation
CA2598456A1 (en) 2005-02-16 2006-08-24 Schering Corporation Heterocyclic substituted piperazines with cxcr3 antagonist activity
CN101610775B (en) * 2006-12-28 2012-12-12 国立大学法人御茶水女子大学 Analgesic agent comprising cyclic phosphatidic acid derivative
JP2010189315A (en) 2009-02-18 2010-09-02 Unitika Ltd Healing accelerator for articular cartilage lesion and food and drink containing the same

Also Published As

Publication number Publication date
SG11201402226PA (en) 2014-10-30
JPWO2013069404A1 (en) 2015-04-02
KR101953181B1 (en) 2019-02-28
ES2634008T3 (en) 2017-09-26
BR112014011315B1 (en) 2020-03-03
AU2012337087A1 (en) 2014-06-05
WO2013069404A1 (en) 2013-05-16
HK1199406A1 (en) 2015-07-03
EP2803359A4 (en) 2015-12-16
MY168931A (en) 2019-01-09
CA2855660C (en) 2019-04-16
US9085593B2 (en) 2015-07-21
BR112014011315A2 (en) 2017-05-09
KR20140098778A (en) 2014-08-08
RU2646457C2 (en) 2018-03-05
EP2803359B1 (en) 2017-04-19
US20140309194A1 (en) 2014-10-16
NZ624870A (en) 2016-01-29
CA2855660A1 (en) 2013-05-16
EP2803359A1 (en) 2014-11-19
AU2012337087B2 (en) 2016-11-17
RU2014123690A (en) 2015-12-20
CN103906519A (en) 2014-07-02
CN103906519B (en) 2017-10-10
JP5465815B2 (en) 2014-04-09
BR112014011315B8 (en) 2020-09-15

Similar Documents

Publication Publication Date Title
AU2024202233A1 (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
PE20151727A1 (en) 2-AZA-BICYCLE ACID [2.2.1] HEPTANE-3-CARBOXYL (BENZYL-CYAN-METHYL) -AMIDES SUBSTITUTED, CATEPSIN C INHIBITORS
UY33370A (en) Pharmaceutical compositions comprising a DPP4 and pioglitazone inhibitor drug, preparation and use procedures
IN2012DN06720A (en)
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
MX2019003693A (en) Long-acting formulations of insulin.
CR20140567A (en) FORMULATIONS AND METHODS FOR THE VAGINAL ADMINISTRATION OF ANTIPROGESTINES
MY163083A (en) Solid forms of a pharmaceutically active substance
MX2015002669A (en) Methods of administering pirfenidone therapy.
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MX2016000794A (en) High potency pancreatin pharmaceutical compositions.
IN2015DN01151A (en)
GEP201706621B (en) Benzamides
MX364220B (en) Methods of treating fibrosis.
MX2016000480A (en) High potency pancreatin pharmaceutical compositions.
JO3388B1 (en) Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
MY173491A (en) Therapeutic or prophylactic agent for biliary tract diseases
MX336333B (en) New crystalline form of a cyclopropyl benzamide derivative.
BR112015011693A2 (en) fibrinolytic compositions comprising bromelain and nattokinase for the prevention and treatment of phlebotrombotic conditions
IN2014CN04222A (en)
MX2015007945A (en) Uses and methods for the treatment of liver diseases or conditions.
IN2014DN03010A (en)
IN2014CN04119A (en)
TR201200215A2 (en) Improved pharmaceutical formulations.
TR201200212A2 (en) Enhanced formulations containing risedronate.